Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
Nexalin Technology (Nasdaq: NXL) has been appointed as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. The company, which specializes in Deep Intracranial Frequency Stimulation (DIFS™), will work with policymakers and stakeholders in Washington, D.C. to advance TBI advocacy and research.
The appointment aligns with Nexalin's ongoing initiatives, including a collaborative study with the University of California, San Diego (UCSD) and the San Diego Veterans Affairs (VA) focused on developing treatments for veterans with TBI. The company is also actively engaging with Congress members to strengthen relationships with federal agencies to improve TBI care and support. Federal spending on TBI is projected to increase significantly.
Nexalin Technology (Nasdaq: NXL) è stata nominata Co-Presidente dell'Industria della Coalizione del Registro Nazionale dei Traumi Cranici (TBI). L'azienda, specializzata nella Stimolazione Frequenziale Intracranica Profonda (DIFS™), collaborerà con i responsabili politici e le parti interessate a Washington, D.C. per promuovere l'advocacy e la ricerca sul TBI.
La nomina è in linea con le iniziative in corso di Nexalin, che includono uno studio collaborativo con l'Università della California, San Diego (UCSD) e i Veterans Affairs di San Diego (VA), focalizzato sullo sviluppo di trattamenti per i veterani con TBI. L'azienda sta anche interagendo attivamente con membri del Congresso per rafforzare le relazioni con le agenzie federali al fine di migliorare la cura e il supporto per il TBI. La spesa federale per il TBI è prevista in aumento significativo.
Nexalin Technology (Nasdaq: NXL) ha sido nombrada como Co-Presidente de la Industria de la Coalición del Registro Nacional de Lesiones Cerebrales Traumáticas (TBI). La empresa, que se especializa en Estimulación de Frecuencia Intracraneal Profunda (DIFS™), trabajará con responsables de políticas y partes interesadas en Washington, D.C. para avanzar en la defensa y la investigación del TBI.
El nombramiento está alineado con las iniciativas continuas de Nexalin, que incluyen un estudio colaborativo con la Universidad de California, San Diego (UCSD) y la Administración de Veteranos de San Diego (VA) centrado en desarrollar tratamientos para veteranos con TBI. La empresa también está comprometida activamente con miembros del Congreso para fortalecer las relaciones con agencias federales con el fin de mejorar la atención y el apoyo al TBI. Se prevé que el gasto federal en TBI aumente significativamente.
Nexalin Technology (Nasdaq: NXL)는 국가 외상성 뇌손상(TBI) 등록부 연합의 산업 공동 의장으로 임명되었습니다. 깊은 두개내 주파수 자극(DIFS™)을 전문으로 하는 이 회사는 TBI 옹호 및 연구를 발전시키기 위해 워싱턴 D.C.의 정책 입안자 및 이해 관계자와 협력할 것입니다.
이번 임명은 Nexalin의 지속적인 이니셔티브와 일치하며, 여기에는 샌디에고 캘리포니아 대학교(UCSD) 및 샌디에고 재향군인청(VA)과의 협동 연구가 포함되어 있으며, TBI로 고통받는 재향군인들을 위한 치료 개발에 초점을 맞추고 있습니다. 이 회사는 TBI 치료 및 지원을 개선하기 위해 연방 기관과의 관계를 강화하기 위해 의회 의원들과 적극적으로 연결하고 있습니다. TBI에 대한 연방 지출은 유의미한 증가가 예상됩니다.
Nexalin Technology (Nasdaq: NXL) a été nommé Co-Président de l'Industrie de la Coalition du Registre National des Traumatismes Crâniens (TBI). L'entreprise, spécialisée dans la Stimulation Fréquentielle Intracranienne Profonde (DIFS™), travaillera avec les décideurs politiques et les parties prenantes à Washington, D.C. pour faire avancer l'advocacy et la recherche sur le TBI.
La nomination s'inscrit dans le cadre des initiatives en cours de Nexalin, y compris une étude collaborative avec l'Université de Californie à San Diego (UCSD) et les Veterans Affairs de San Diego (VA) axée sur le développement de traitements pour les vétérans atteints de TBI. L'entreprise s'engage également activement avec des membres du Congrès pour renforcer les relations avec les agences fédérales afin d'améliorer les soins et le soutien du TBI. Les dépenses fédérales consacrées au TBI devraient connaître une augmentation significative.
Nexalin Technology (Nasdaq: NXL) wurde zum Co-Vorsitzenden der Branche der Nationalen Koalition zum Register für traumatische Hirnverletzungen (TBI) ernannt. Das Unternehmen, das sich auf tiefe intrakranielle Frequenzstimulation (DIFS™) spezialisiert hat, wird mit politischen Entscheidungsträgern und Interessenvertretern in Washington, D.C. zusammenarbeiten, um die Förderung und Forschung zu TBI voranzutreiben.
Die Ernennung steht im Einklang mit den laufenden Initiativen von Nexalin, einschließlich einer gemeinsamen Studie mit der Universität Kalifornien in San Diego (UCSD) und den Veterans Affairs in San Diego (VA), die sich auf die Entwicklung von Behandlungen für Veteranen mit TBI konzentriert. Das Unternehmen engagiert sich auch aktiv mit Mitgliedern des Kongresses, um die Beziehungen zu Bundesbehörden zu stärken und die Versorgung und Unterstützung von TBI zu verbessern. Die Bundesausgaben für TBI werden voraussichtlich erheblich steigen.
- Appointment as Industry Co-Chair strengthens company's position in TBI sector
- Ongoing collaboration with UCSD and VA for veteran treatment studies
- Strategic engagement with federal legislators and agencies
- Positioned to benefit from projected increase in federal TBI spending
- None.
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its appointment as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment emphasizes Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders in Washington, D.C.
"We are honored to be named Industry Co-Chair of the National TBI Registry Coalition," said Mark White, CEO of Nexalin. "This role reflects our dedication to improving the lives of those affected by traumatic brain injuries. With federal spending on TBI projected to increase significantly, we are committed to working closely with policymakers and stakeholders in Washington to advance meaningful solutions that address the needs of this underserved population."
This leadership role complements Nexalin's ongoing initiatives, including a collaborative study with the University of California, San Diego (UCSD), and the San Diego Veterans Affairs (VA) to explore innovative treatments for veterans suffering from TBI.
Furthermore, Nexalin has been actively engaging with key legislators across Congress to strengthen relationships with federal agencies, aiming to enhance TBI care and support. The Company anticipates sharing additional developments in the near future.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What is Nexalin's (NXL) new role in the National TBI Registry Coalition?
What research partnerships does Nexalin (NXL) have for TBI treatment?
How is Nexalin (NXL) positioned to benefit from federal TBI spending?
What technology does Nexalin (NXL) use for brain treatment?
